436 results
Keyword paclitaxel Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Abraxane
paclitaxel, Breast Neoplasms, Pancreatic Neoplasms, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 11/01/2008, Revision: 27, Authorised, Last updated: 25/11/2020Authorised paclitaxel Overview This is a summary … contains the active substance paclitaxel attached to a human protein … other medicines containing paclitaxel. Abraxane is given into a … -
List item
Human medicine European public assessment report (EPAR): Pazenir
paclitaxel, Breast Neoplasms
Date of authorisation: 06/05/2019,
, Revision: 5, Authorised, Last updated: 24/06/2020
Authorised paclitaxel Overview Pazenir is used … contains the active substance paclitaxel attached to a human protein … other medicines containing paclitaxel. The medicine can only be … -
List item
Human medicine European public assessment report (EPAR): Apealea
paclitaxel, Ovarian Neoplasms
Date of authorisation: 20/11/2018, Revision: 3, Authorised, Last updated: 04/03/2020Authorised paclitaxel Overview Apealea is a cancer … contains the active substance paclitaxel. How is Apealea used? Apealea … infusion (drip) into a vein. The paclitaxel in Apealea is formulated … -
List item
Human medicine European public assessment report (EPAR): Paxene
paclitaxel, Sarcoma, Kaposi, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Breast Neoplasms
Date of authorisation: 19/07/1999, Revision: 14, Withdrawn, Last updated: 22/03/2010Withdrawn paclitaxel Overview The marketing authorisation … Public statement on Paxene (paclitaxel): Withdrawal of the marketing … Public statement on Paxene (paclitaxel) Withdrawal of the marketing … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Abraxane, paclitaxel
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001308-PIP01-12-M02, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for suspension for injection
Decision date: 14/08/2018, Last updated: 19/12/2018, Compliance check: V, 21/09/2018Key facts Abraxane paclitaxel OncologyP/0257/2018EMEA-001308-PIP01-12-M02 … paediatric investigation plan for paclitaxel Abraxane), (EMEA-001308-PIP01-12-M02 … Abraxane Abraxane paclitaxel paclitaxel paclitaxel … -
List item
Withdrawn application: Paccal Vet
paclitaxel, date of withdrawal: 02/03/2012, Initial authorisation, Last updated: 25/04/2012Paccal Vet Paccal Vet paclitaxel paclitaxel … -
List item
Orphan designation: Paclitaxel-succinate-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe for: Treatment of glioma
Date of first decision: 04/06/2014, Positive, Last updated: 27/05/2015to CLL Pharma, France, for paclitaxel-succinate-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe for the treatment of glioma … opinion on orphan designation Paclitaxel-succinate-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe for the treatment of glioma … opinion on orphan designation Paclitaxel-succinate-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe for the treatment of glioma … -
List item
Referral: Paclitaxel Hetero and associated names
paclitaxel, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 18/10/2018, EC decision date: 11/01/2019, Last updated: 21/01/2019Paclitaxel Hetero and associated names … EMA) completed a review of Paclitaxel Hetero following a disagreement … concluded that the benefits of Paclitaxel Hetero do not outweigh its … -
List item
Orphan designation: paclitaxel for: Treatment of ovarian cancer
Date of first decision: 17/12/2006, Withdrawn, Last updated: 05/12/2018Pharmaceutical AB, Sweden, for paclitaxel (micellar) for the treatment … subsequent chemotherapy. Paclitaxel (micellar) might be of potential … help during cell-division. Paclitaxel (micellar) blocks the microtubules … -
List item
Orphan designation: paclitaxel for: Treatment of pancreatic cancer
Date of first decision: 31/10/2006, Positive, Last updated: 16/08/2016MediGene AG, Germany, for paclitaxel (liposomal) for the treatment … justify the assumption that paclitaxel (liposomal) might be of potential … disassemble in a very orderly way. Paclitaxel interferes with the assembly … -
List item
Orphan designation: paclitaxel for: Treatment of oesophagus carcinoma
Date of first decision: 23/02/2011, Positive, Last updated: 04/03/2011plc, United Kingdom, for paclitaxel (aqueous gel) for the treatment … information to show that paclitaxel (aqueous gel) might be of … medicine expected to work? Paclitaxel has been available as an … -
List item
Orphan designation: paclitaxel for: Treatment of soft tissue sarcoma
Date of first decision: 17/10/2019, Positive, Last updated: 23/01/2020Consultants Limited, Ireland, for paclitaxel for the treatment of soft … patients were treated with paclitaxel, given by mouth, plus another … EU/3/19/2207), that allows paclitaxel to work when given by mouth … -
List item
Orphan designation: Nanoparticle albumin-bound paclitaxel for: Treatment of pancreatic cancer
Date of first decision: 26/11/2010, Withdrawn, Last updated: 11/03/2013nanoparticle albumin-bound paclitaxel for the treatment of pancreatic … Nanoparticle albumin-bound paclitaxel is already authorised in … medicine expected to work? Paclitaxel, the active substance in nanoparticle … -
List item
Press release: CTI Life Sciences Ltd. withdraws its marketing authorisation application for Opaxio (paclitaxel poliglumex)
Last updated: 23/09/2009authorisation application for Opaxio (paclitaxel poliglumex … for the medicine Opaxio (paclitaxel poliglumex), 269 mg powder … authorisation application for Opaxio (paclitaxel poliglumex) PDF icon application/pdf … -
List item
News: EMA reminds physicians to use Tecentriq with nab-paclitaxel for treating breast cancer
Last updated: 01/10/2020to use Tecentriq with nab-paclitaxel for treating breast cancer … to use Tecentriq with nab-paclitaxel for treating breast cancer … -
List item
Human medicine European public assessment report (EPAR): Avastin
bevacizumab, Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell
Date of authorisation: 12/01/2005, Revision: 57, Authorised, Last updated: 24/02/2021cancer, in combination with paclitaxel or capecitabine; advanced … given in combination with paclitaxel and either the platinum-based … used in combination with paclitaxel (an anticancer medicine belonging … -
List item
Human medicine European public assessment report (EPAR): Tecentriq
atezolizumab, Carcinoma, Transitional Cell, Carcinoma, Non-Small-Cell Lung, Urologic Neoplasms, Breast Neoplasms, Small Cell Lung Carcinoma
Date of authorisation: 20/09/2017,
, Revision: 13, Authorised, Last updated: 05/03/2021
given Tecentriq together with paclitaxel, carboplatin and bevacizumab … getting worse while those given paclitaxel, carboplatin and bevacizumab … with carboplatin plus nab-paclitaxel compared with 13.9 months … -
List item
Human medicine European public assessment report (EPAR): Mvasi
bevacizumab, Carcinoma, Renal Cell, Peritoneal Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms
Date of authorisation: 15/01/2018,, 
, Revision: 9, Authorised, Last updated: 03/11/2020
medicines carboplatin and paclitaxel. The cancer responded to treatment … -
List item
Human medicine European public assessment report (EPAR): Aybintio (updated)
bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020,, , Revision: 2, Authorised, Last updated: 06/04/2021
with the cancer medicines paclitaxel and carboplatin. The cancer … Aybintio in combination with paclitaxel is indicated for first-line … combination with carboplatin and paclitaxel is indicated for the front-line … -
List item
Human medicine European public assessment report (EPAR): Equidacent
bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
Date of authorisation: 24/09/2020,, , Revision: 1, Authorised, Last updated: 16/11/2020
with the cancer medicines paclitaxel and carboplatin. After around … -
List item
Human medicine European public assessment report (EPAR): Cyramza
Ramucirumab, Stomach Neoplasms
Date of authorisation: 19/12/2014, Revision: 11, Authorised, Last updated: 02/07/2020treated with Cyramza and paclitaxel lived longer than patients … longer than patients receiving paclitaxel and placebo (a dummy treatment … “Cyramza in combination with paclitaxel is indicated for the treatment … -
List item
Human medicine European public assessment report (EPAR): Keytruda (updated)
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urologic Neoplasms, Squamous Cell Carcinoma of Head and Neck
Date of authorisation: 17/07/2015,, Revision: 32, Authorised, Last updated: 31/03/2021
Keytruda with carboplatin and paclitaxel or nab paclitaxel lived on average for 15.9 … placebo with carboplatin and paclitaxel or nab paclitaxel. Patients in the Keytruda … -
List item
Human medicine European public assessment report (EPAR): Zirabev
bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 14/02/2019,, , Revision: 7, Authorised, Last updated: 07/01/2021
medicines carboplatin and paclitaxel. The cancer improved in 45 … rectum. Zirabev in combination with paclitaxel is indicated for first-line … combination with carboplatin and paclitaxel is indicated for the front-line … -
List item
Human medicine European public assessment report (EPAR): Herceptin
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 28/08/2000, Revision: 38, Authorised, Last updated: 27/08/2020anticancer medicines: with paclitaxel or docetaxel, or with an … Herceptin in combination with paclitaxel or docetaxel in a total of … used in combination with paclitaxel or docetaxel, around half … -
List item
Human medicine European public assessment report (EPAR): Onbevzi
bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 11/01/2021,, , Authorised, Last updated: 05/03/2021
with the cancer medicines paclitaxel and carboplatin. The cancer … with the cancer medicines paclitaxel and carboplatin. The cancer … Onbevzi in combination with paclitaxel is indicated for first-line …